Clarient
HCID Member | Healthcare Services
31 Columbia
Aliso Viejo, CA 92656 USA
phone: 949-425-5700
fax: 949-425-5701
Symbol CLRT
Exchange NASDAQ
Founded 1993
Employees 208
www.clarientinc.com
Research Sector Healthcare Services
Summary Description
Comprehensive Anatomic Pathology and Molecular Testing Services
Management
RON A. ANDREWS, Chief Executive Officer & Vice Chairman of the Board; Michael J. Pellini, President & Chief Operating Officer; Raymond J. Land, Senior Vice President & Chief Financial Officer; David J. Daly, Senior Vice President, Commercial Operations, Kenneth J. Bloom, Chief Medical Director
Ownership
Financials Mkt Cap :20


* numbers in thousands

 
Keywords
h pylori test, helicobacter pylori test, cancer, diagnostics, pathology, cellular imaging, personalized medicine,

Comment | Printable Version | Jul. 03, 2009
If you work for Clarient and want to update this profile, click here

Description
Clarient provides advanced anatomic pathology and molecular testing services for pathologists, oncologists and the pharmaceutical industry. It specializes in comprehensive cancer diagnostic services, including: diagnosis of solid tumors, as well as leukemia and lymphoma, cancer sub-typing, patient classification into prognostic categories (i.e. low, medium and high risk groups), identification of the optimal drug and therapy strategy for individual patients, and monitoring of patients undergoing therapy.
Products / Services
Clarient's fully licensed state-of-the-art advanced cancer laboratory provides full, comprehensive laboratory services that include in-house pathology testing using cutting-edge diagnostics. The company's Bioanalytical Service group (a team of prominent scientists and assay development specialists) offers tools and resources to support specialized investigative efforts. Clarient is also engaging in collaborative partnerships with major pharmaceutical companies to help develop their leading drug candidates.
Technology / Differentiation
Clarient's diagnostics spans the full spectrum of cellular analysis, including: protein identification by immunohistochemistry, DNA and RNA analysis using molecular PCR and in situ hybridization, and cellular categorizing by flow cytometry.
Market / Customers
Clarient has reported that the market for advanced cancer diagnostic testing will increase to over $3.0 billion by 2012. This increase is attributable to multiple factors, including increasing incidence of cancer in an aging population, development of new therapies, and expanded testing panels. The company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
Status
Based on its study results released in December 2008, Clarient announced that its Insight Dx will accurately predict future event risk in operable hormone-receptor-positive breast cancer patients, achieve significantly higher classification accuracy than current clinical practice treatment guidelines and aid selection of the optimal level of adjuvant therapy. The company launched two predictive biomarkers for colorectal cancer in 2008, BRAF and KRAS; the latter product (marketed since July 2008) has a current revenue run rate of over $5 million per year.


2009-07-04-2948